Physician profile
Chizor Odibi
NPI 1477702462
$774.16
in general payments reported to CMS, 2019-2025
15 companies · $89.06 in 2025
The $89.06 reported for 2025 was more than what a typical Hospice and Palliative Medicine (Internal Medicine) provider received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.30 · 2020: $16.47 · 2021: $15.92 · 2022: $252 · 2023: $134 · 2024: $216 · 2025: $89.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $128.58 | 2019-2024 | Xarelto |
| Abbott Laboratories | $123.92 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $120.27 | 2022 | |
| Abbvie INC. | $71.98 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.32 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.41 | 2023 | Jardiance |
| Abiomed | $39.83 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.74 | 2025 | Lifevest |
| Corcept Therapeutics | $35.39 | 2023 | Korlym |
| Pfizer INC. | $33.76 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.44 | 2024 | Eliquis |
| Novartis Pharmaceuticals Corporation | $15.92 | 2021 | |
| Allergan, INC. | $13.33 | 2019 | |
| Merck Sharp & Dohme LLC | $11.68 | 2022 | |
| Advanced Respiratory, INC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chizor Odibi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.